Temsirolimus

A protein kinase inhibitor called a mammalian target of rapamycin (mTOR) inhibitor used for the treatment of advanced kidney cancer with a poor outlook (prognosis). mTOR inhibitors act in a similar manner to TKIs by interfering with the signalling pathway that controls tumour cell growth and growth of new blood vessels (angiogenesis) into a solid tumour, thereby starving the tumour of nutrients and oxygen needed for growth. Temsirolimus is a type of angiogenesis inhibitor. Temsirolimus is the chemical (or generic) name of the drug, while Torisel is the brand (or trade) name under which the drug is licensed and sold.